Seattle Institute For Biomedical And Clinical Research

Seattle Institute For Biomedical And Clinical Research, doing business as Seattle Institute, is a Seattle-based tax-exempt nonprofit organization that functions as a research recipient and sub-recipient for federal biomedical and clinical research grants, predominantly from the National Institutes of Health and the Defense Health Agency. The Institute acts primarily as a grant recipient (64% prime awards) on a portfolio of 175 recent federal awards spanning neurodegenerative disease, metabolic disorders, traumatic brain injury, and substance use disorder research.

The Institute's research footprint centers on fundamental and translational biomedical investigation. Representative prime grant work includes a $374,550 National Institute of General Medical Sciences project grant awarded June 2026 investigating molecular regulation of endothelial glycocalyx-mediated transcytosis using radiochemical-based assays; a $474,762 National Institute on Alcohol Abuse and Alcoholism project grant awarded May 2026 examining blast-induced traumatic brain injury and chronic alcohol use effects on neurodegeneration in rodent models; a $1,557,602 NIH Office of the Director research support award (CFDA 93.310) awarded August 2025 for the "OPTIMIZE Lung-HIV" multicenter effectiveness-implementation trial testing pharmacist-led e-consults for people with HIV across Veterans Health Administration sites; and a $2,181,250 National Institute on Aging research grant awarded September 2023 developing small-molecule inhibitors of the MSUT2 protein as a therapeutic approach for tauopathy disorders. The Institute also receives sub-awards as a research site—for example, a $214,688 sub-award from the University of Washington supporting neuropathologic work under a Defense Health Agency grant on glymphatics imaging in Parkinson's disease. In subcontractor roles, Seattle Institute typically provides research coordination, data management, and subject assessment services to university prime grantees.

Customer concentration is heavily weighted to basic and clinical neuroscience funding. The top three funders account for 65% of recent awards by count: the National Institute on Aging leads with 44 awards; NIH broadly contributes 21 awards; the National Institute of Diabetes and Digestive and Kidney Diseases holds 18 awards; and the Defense Health Agency provides 19 awards with the entire $4.5 million combined potential value in the source. Activity has accelerated year over year—9 awards in 2022 to 28 in 2024—with 13 awards recorded in 2026 to date. Twenty-three awards face ultimate completion within the next twenty-four months, representing the full $4.5 million in combined potential value.

Seattle Institute operates as a flexible funding mechanism affiliated with VA Puget Sound Health Care System and serves as a research facilitation entity under 38 U.S. Code 7361. The organization coordinates research and education initiatives, manages regulatory and compliance infrastructure for VA-affiliated research, and provides administrative support to investigators housed at the VA Puget Sound system. The Institute's research output includes peer-reviewed publications, novel animal models and conditional viral vector tools, biomarker discovery, and clinical trial data from effectiveness-implementation studies. The portfolio reflects deep expertise in glymphatic system dysfunction, tau pathology mechanisms, and blast-related traumatic brain injury—areas of particular focus for both the NIH Institutes and the Defense Health Agency in recent years.